美国联邦医疗保险人群中女性脆性骨折后的治疗差距及后续骨折风险研究
该回顾性观察性队列研究利用美国联邦医疗保险数据库,纳入2011年因脆性骨折就诊的65岁以上女性,评估骨质疏松药物治疗的预测因素及治疗对12个月内后续骨折风险的影响。结果显示27.7%的女性在骨折后12个月内接受骨质疏松药物治疗,治疗使后续骨折风险降低21%(HR=0.79,95%CI 0.75-0.83)。黑人种族、较高查尔森合并症指数评分、痴呆和肾脏疾病与较低的用药可能性相关。
要点
- 骨折后12个月内仅27.7%的女性接受骨质疏松药物治疗,72.2%未治疗。
- 骨折前使用骨质疏松药物是骨折后用药最强的正向预测因素(HR=7.87,95%CI 7.67-8.07)。
- 骨质疏松药物治疗使12个月内后续骨折风险降低21%(HR=0.79,95%CI 0.75-0.83)。
核心结论
- 人口学和临床特征是骨质疏松药物使用的强预测因素。
- 在美国联邦医疗保险人群中,骨质疏松治疗显著降低脆性骨折风险。
研究设计与样本
- 回顾性观察性队列研究,使用美国联邦医疗保险数据库。
- 纳入2011年1月1日至2011年12月31日期间因脆性骨折住院或接受门诊/急诊服务的65岁及以上女性。
- 共纳入28,722例(27.7%)在索引骨折后12个月内接受骨质疏松药物治疗的女性和74,979例(72.2%)未治疗女性。
主要发现
- 骨折前使用骨质疏松药物是骨折后用药最强的正向预测因素(HR=7.87;95%CI 7.67-8.07)。
- 黑人种族、较高查尔森合并症指数评分、痴呆和肾脏疾病与较低的骨质疏松药物使用可能性相关。
- 与未治疗女性相比,骨质疏松药物治疗使12个月内后续骨折风险降低21%(HR=0.79,95%CI 0.75-0.83)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Our aim was to evaluate the gap in osteoporosis treatment and the impact of osteoporosis treatment on subsequent fragility fractures. We found osteoporosis medication use lowered risk of subsequent fractures by 21% and that black race, higher CCI scores, dementia, and kidney diseases reduced the likelihood of osteoporosis medication use. INTRODUCTION: The goal of this study was to evaluate the predictors of osteoporosis medication use and compare the risk of fragility fractures within 1 year of a fragility fracture between osteoporosis treated and untreated women. METHODS: We conducted a retrospective, observational cohort study using the national Medicare database. Elderly women (≥65 years) who were hospitalized or had an outpatient/ER service for fragility fracture between January 1, 2011 and December 31, 2011 were included. The outcomes of interest were the correlates of and time-to-osteoporosis medication use and risk of a subsequent fracture within 12 months for treated and untreated women. Cox regression was used to evaluate the predictors of treatment use and the risk of fracture based on treatment status. RESULTS: Women (28,722) (27.7%) were treated with osteoporosis medication within 12 months of index fracture, and 74,979 (72.2%) were untreated. A number of patient characteristics were associated with a reduced likelihood of osteoporosis medication use, including black race, higher Charlson comorbidity index scores, presence of dementia, and kidney diseases in the baseline. The predictor most strongly and positively associated with osteoporosis medication use after fracture was osteoporosis medication use before fragility fracture (HR = 7.87; 95% CI 7.67-8.07). After adjusting for baseline characteristics, osteoporosis medication use lowered the risk of subsequent fractures by 21% (HR = 0.79, 95% CI 0.75-0.83) over 12 months compared to women without treatment. CONCLUSIONS: Demographics and clinical characteristics were strong predictors of osteoporosis medication use. In the US Medicare population, osteoporosis treatment significantly reduced the risk of fragility fractures.
引用
- Keshishian A, Boytsov N, Burge R, et al. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int. 2017. PMID: 28536737. doi:10.1007/s00198-017-4072-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。